AT Bancorp decreased its position in Medtronic PLC (NYSE:MDT) by 56.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,724 shares of the medical technology company’s stock after selling 7,538 shares during the quarter. AT Bancorp’s holdings in Medtronic were worth $490,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of MDT. BlackRock Inc. raised its position in Medtronic by 1.4% during the 1st quarter. BlackRock Inc. now owns 95,900,878 shares of the medical technology company’s stock worth $7,693,168,000 after purchasing an additional 1,305,298 shares during the last quarter. Artisan Partners Limited Partnership raised its position in Medtronic by 1.8% during the 1st quarter. Artisan Partners Limited Partnership now owns 22,504,041 shares of the medical technology company’s stock worth $1,805,274,000 after purchasing an additional 392,687 shares during the last quarter. Bank of New York Mellon Corp raised its position in Medtronic by 11.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 15,717,199 shares of the medical technology company’s stock worth $1,345,549,000 after purchasing an additional 1,589,932 shares during the last quarter. Wells Fargo & Company MN raised its position in Medtronic by 5.9% during the 1st quarter. Wells Fargo & Company MN now owns 13,941,900 shares of the medical technology company’s stock worth $1,118,419,000 after purchasing an additional 782,123 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Medtronic by 2.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 7,182,755 shares of the medical technology company’s stock worth $576,200,000 after purchasing an additional 159,941 shares during the last quarter. 80.13% of the stock is currently owned by institutional investors.

Several research analysts recently issued reports on the company. Sanford C. Bernstein assumed coverage on Medtronic in a research report on Wednesday, June 27th. They set a “market perform” rating and a $88.00 target price for the company. Oppenheimer reaffirmed a “buy” rating and set a $96.00 target price on shares of Medtronic in a research report on Thursday, May 24th. SunTrust Banks raised their target price on Medtronic to $96.00 and gave the stock a “buy” rating in a research report on Monday, May 21st. William Blair assumed coverage on Medtronic in a research report on Wednesday, June 6th. They set a “market perform” rating for the company. Finally, TheStreet raised Medtronic from a “c+” rating to a “b-” rating in a research report on Monday, May 21st. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $93.24.

Shares of MDT opened at $90.60 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.28 and a quick ratio of 1.92. The stock has a market capitalization of $122.46 billion, a PE ratio of 19.14, a PEG ratio of 2.46 and a beta of 0.94. Medtronic PLC has a one year low of $76.41 and a one year high of $91.50.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Thursday, May 24th. The medical technology company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. The business had revenue of $8.14 billion during the quarter, compared to the consensus estimate of $8 billion. Medtronic had a return on equity of 12.84% and a net margin of 10.36%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.33 EPS. sell-side analysts forecast that Medtronic PLC will post 5.11 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 25th. Shareholders of record on Friday, July 6th were paid a dividend of $0.50 per share. The ex-dividend date was Thursday, July 5th. This represents a $2.00 dividend on an annualized basis and a yield of 2.21%. This is an increase from Medtronic’s previous quarterly dividend of $0.46. Medtronic’s payout ratio is 41.93%.

In other Medtronic news, SVP Bradley E. Lerman sold 8,910 shares of Medtronic stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $86.82, for a total transaction of $773,566.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Richard Kuntz sold 11,500 shares of Medtronic stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $87.13, for a total value of $1,001,995.00. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Read More: What does RSI mean?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.